Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 9.8%

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) fell 9.8% during trading on Monday . The stock traded as low as $1.07 and last traded at $1.10, 504,147 shares traded hands during mid-day trading. An increase of 107% from the average session volume of 244,048 shares. The stock had previously closed at $1.22.

Several brokerages have commented on ADAP. ValuEngine upgraded Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Zacks Investment Research downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Guggenheim downgraded Adaptimmune Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, August 1st. Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Monday, September 30th. Finally, BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 26th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $6.59.

The stock has a market cap of $127.72 million, a P/E ratio of -1.15 and a beta of 1.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 6.19 and a current ratio of 6.19. The stock has a 50-day moving average price of $1.59 and a 200-day moving average price of $3.17.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.07). The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $4.25 million. Sell-side analysts forecast that Adaptimmune Therapeutics PLC – will post -1.28 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Bamco Inc. NY boosted its position in shares of Adaptimmune Therapeutics by 6.1% during the 2nd quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock valued at $694,000 after acquiring an additional 10,000 shares during the last quarter. Man Group plc boosted its position in shares of Adaptimmune Therapeutics by 37.4% during the 2nd quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock valued at $7,394,000 after acquiring an additional 500,595 shares during the last quarter. Rock Springs Capital Management LP boosted its position in shares of Adaptimmune Therapeutics by 9.4% during the 2nd quarter. Rock Springs Capital Management LP now owns 875,000 shares of the biotechnology company’s stock valued at $3,518,000 after acquiring an additional 75,000 shares during the last quarter. Rathbone Brothers plc boosted its position in shares of Adaptimmune Therapeutics by 146.6% during the 2nd quarter. Rathbone Brothers plc now owns 704,472 shares of the biotechnology company’s stock valued at $2,832,000 after acquiring an additional 418,750 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its position in shares of Adaptimmune Therapeutics by 7.9% during the 2nd quarter. Baillie Gifford & Co. now owns 4,143,840 shares of the biotechnology company’s stock valued at $16,658,000 after acquiring an additional 304,650 shares during the last quarter. Hedge funds and other institutional investors own 65.15% of the company’s stock.

About Adaptimmune Therapeutics (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Further Reading: Golden Cross

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.